In this episode, listen to Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands.
In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:
Presenters:
Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom
Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands
Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.
Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL